Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foreign Drug Inspections Would Be Funded By Registration Fees In Draft U.S. Bill

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA inspections of overseas drug producers would be supported by annual registration fees under a legislative "discussion draft" being circulated by House Energy and Commerce Committee Chairman John Dingell, D-Mich.

You may also be interested in...



Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats

Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered.

Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats

Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered.

U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation

The House Energy & Commerce Subcommittee on Oversight and Investigations simultaneously lauded and criticized U.S. FDA's handling of the heparin contaminant safety issue, which FDA now says was most likely the result of intentional actions

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC068244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel